co‐administered stimulators of interferon‐gamma (STING) agonists with CAR‐T cells to treat pancreatic tumors in mice.[53] Engaging the STING pathway upregulates type 1 IFN production and promotes DC activation; STING agonists have been used as effective adjuvants to achieve cancer‐specific treatment.[54] and prime the CD8+ T cells for a tumor‐specific response.[55, 56] In this approach, the eradicated cancer cells act as a source of cancer antigens, which combined with the adjuvant, launched a specific antitumor response. Here, CD8A is linked to neoplasm.